Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-5: MET097 in Overweight/Obesity and Type 2 Diabetes
NCT07400653Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Peptides
- Countries
- 11
01
Overview
A Phase 3 trial of PF-08653944 in obesity, type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Started Feb 2026; status: active, not recruiting.
02
Drugs
PF-08653944
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07400653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400653.